Users Online: 185
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

DRUG REVIEW

Crizotinib: A comprehensive review

Sahu Arvind, Prabhash Kumar, Noronha Vanita, Joshi Amit, Desai Saral

Year : 2013| Volume: 2| Issue : 2 | Page no: 91-97

   This article has been cited by
 
1 C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview
Wafaa M. Rashed
Critical Reviews in Oncology/Hematology. 2018; 131: 7
[Pubmed]  [Google Scholar] [DOI]
2 Synthesis, molecular structure, and metabolic stability of new series of Næ -(2-alkylthio-4-chloro-5-methylbenzenesulfonyl)-1-(5-phenyl-1 H -pyrazol-1-yl)amidine as potential anti-cancer agents
Aneta Pogorzelska,Jaroslaw Slawinski,Anna Kawiak,Beata Zolnowska,Jaroslaw Chojnacki,Grzegorz Stasilojc,Szymon Ulenberg,Krzysztof Szafranski,Tomasz Baczek
European Journal of Medicinal Chemistry. 2018; 155: 670
[Pubmed]  [Google Scholar] [DOI]
3 Effective Treatment of Choroidal Metastasis With ALK Inhibitor Chemotherapy That Crosses the Blood–Brain Barrier
Michael Possin,Michael Altaweel
Journal of VitreoRetinal Diseases. 2018; 2(2): 115
[Pubmed]  [Google Scholar] [DOI]
4 The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’
Patrick Schöffski,Agnieszka Wozniak,Michael G. Leahy,Steinar Aamdal,Piotr Rutkowski,Sebastian Bauer,Stephan Richter,Viktor Grünwald,Maria Debiec-Rychter,Raf Sciot,Birgit Geoerger,Sandrine Marréaud,Sandra Collette,Axelle Nzokirantevye,Sandra J. Strauss
European Journal of Cancer. 2018; 94: 156
[Pubmed]  [Google Scholar] [DOI]
5 Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Takeshi Hirota,Shota Muraki,Ichiro Ieiri
Clinical Pharmacokinetics. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
Patrick Schöffski,Jozef Sufliarsky,Hans Gelderblom,Jean-Yves Blay,Sandra J Strauss,Silvia Stacchiotti,Piotr Rutkowski,Lars H Lindner,Michael G Leahy,Antoine Italiano,Nicolas Isambert,Maria Debiec-Rychter,Raf Sciot,Thomas Van Cann,Sandrine Marréaud,Axelle Nzokirantevye,Sandra Collette,Agnieszka Wozniak
The Lancet Respiratory Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
Jianya Zhou,Jing Zheng,Xiaochen Zhang,Jing Zhao,Yanping Zhu,Qian Shen,Yuehong Wang,Ke Sun,Zeying Zhang,Zhijie Pan,Yihong Shen,Jianying Zhou
BMC Cancer. 2018; 18(1)
[Pubmed]  [Google Scholar] [DOI]
8 Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants
Natalia V. Mitiushkina,Vladislav I. Tiurin,Aglaya G. Iyevleva,Maxim M. Kholmatov,Elena A. Filippova,Fedor V. Moiseyenko,Nikita E. Levchenko,Ivan S. Sardaryan,Svetlana V. Odintsova,Alexandra M. Lozhkina,Nikita M. Volkov,Nina A. Karaseva,Vladimir M. Moiseyenko,Sergey V. Orlov,Evgeny N. Imyanitov
Biochimie. 2018; 154: 19
[Pubmed]  [Google Scholar] [DOI]
9 Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Junlong Li,Stefanie Knoll,Iryna Bocharova,Wenxi Tang,James Signorovitch
Current Medical Research and Opinion. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
10 Axl inhibitors as novel cancer therapeutic agents
Yingying Shen,Xiguang Chen,Jun He,Duanfang Liao,Xuyu Zu
Life Sciences. 2018;
[Pubmed]  [Google Scholar] [DOI]
11 A major component of vitamin E, a-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK
Yuki Uchihara,Takayuki Kidokoro,Kenji Tago,Tadahiko Mashino,Hiroomi Tamura,Megumi Funakoshi-Tago
European Journal of Pharmacology. 2018; 825: 1
[Pubmed]  [Google Scholar] [DOI]
12 Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK
Yuki Uchihara,Fumihito Ueda,Kenji Tago,Yosuke Nakazawa,Tomoyuki Ohe,Tadahiko Mashino,Shigenobu Yokota,Tadashi Kasahara,Hiroomi Tamura,Megumi Funakoshi-Tago,Jung Weon Lee
PLOS ONE. 2017; 12(8): e0183003
[Pubmed]  [Google Scholar] [DOI]
13 Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
P Schöffski,A Wozniak,B Kasper,S Aamdal,M G Leahy,P Rutkowski,S Bauer,H Gelderblom,A Italiano,L H Lindner,I Hennig,S Strauss,B Zakotnik,A Anthoney,L Albiges,J -Y Blay,P Reichardt,J Sufliarsky,W T A van der Graaf,M Debiec-Rychter,R Sciot,T Van Cann,S Marréaud,T Raveloarivahy,S Collette,S Stacchiotti
Annals of Oncology. 2017;
[Pubmed]  [Google Scholar] [DOI]
14 Use of precision methods to accelerate drug development in oncology
Geraldine O’Sullivan Coyne,S. Percy Ivy,Barbara A. Conley
Expert Review of Precision Medicine and Drug Development. 2017; 2(2): 109
[Pubmed]  [Google Scholar] [DOI]
15 Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer
Avital Lev,Safoora Deihimi,Elena Shagisultanova,Joanne Xiu,Amriti R. Lulla,David T. Dicker,Wafik S. El-Deiry
Cancer Biology & Therapy. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
16 Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
Candice C. Poon,John J. Kelly
International Journal of Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]
17 Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
P. Schöffski,A. Wozniak,S. Stacchiotti,P. Rutkowski,J.-Y. Blay,L. H. Lindner,S. J. Strauss,A. Anthoney,F. Duffaud,S. Richter,V. Grünwald,M. G. Leahy,P. Reichardt,J. Sufliarsky,W. T. van der Graaf,R. Sciot,M. Debiec-Rychter,T. van Cann,S. Marréaud,M. Lia,T. Raveloarivahy,L. Collette,S. Bauer
Annals of Oncology. 2017;
[Pubmed]  [Google Scholar] [DOI]
18 HPLC method development and validation for the estimation of axitinibe in rabbit plasma
Achanta Suneetha,Sharmila Donepudi
Brazilian Journal of Pharmaceutical Sciences. 2017; 53(3)
[Pubmed]  [Google Scholar] [DOI]
19 F1174V Mutation Alters the ALK Active Conformation in Response to Crizotinib in NSCLC: Insight from Molecular Simulations
Fariba Dehghanian,Maryam Kay,Sadeq Vallian
Journal of Molecular Graphics and Modelling. 2017;
[Pubmed]  [Google Scholar] [DOI]
20 Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro
Ali Raza,Steven R. Kopp,Andrew C. Kotze
Veterinary Parasitology. 2016; 227: 64
[Pubmed]  [Google Scholar] [DOI]
21 Crizotinib: from discovery to accelerated development to front-line treatment
F. Blackhall,F. Cappuzzo
Annals of Oncology. 2016; 27(suppl_3): iii35
[Pubmed]  [Google Scholar] [DOI]
22 ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer
Haiyan Sun,Christopher G. England,Reinier Hernandez,Stephen A. Graves,Rebecca L. Majewski,Anyanee Kamkaew,Dawei Jiang,Todd E. Barnhart,Yunan Yang,Weibo Cai
European Journal of Nuclear Medicine and Molecular Imaging. 2016;
[Pubmed]  [Google Scholar] [DOI]
23 Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth
Coralie Hoareau-Aveilla,Thibaud Valentin,Camille Daugrois,Cathy Quelen,Géraldine Mitou,Samuel Quentin,Jinsong Jia,Salvatore Spicuglia,Pierre Ferrier,Monica Ceccon,Sylvie Giuriato,Carlo Gambacorti-Passerini,Pierre Brousset,Laurence Lamant,Fabienne Meggetto
Journal of Clinical Investigation. 2015; 125(9): 3505
[Pubmed]  [Google Scholar] [DOI]
24 Pharmacogenomics and targeted therapy of Cancer: Focusing on Non-small cell lung Cancer
Seyyed Mortaza Haghgoo,Abdolamir Allameh,Esmaeil Mortaz,Johan Garssen,Gert Folkerts,Peter J. Barnes,Ian M. Adcock
European Journal of Pharmacology. 2015;
[Pubmed]  [Google Scholar] [DOI]
25 A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
Alana Dikopf,Kevin Wood,Ravi Salgia
Expert Opinion on Drug Safety. 2015; 14(3): 485
[Pubmed]  [Google Scholar] [DOI]
26 RESPONSE OF UVEAL METASTASES TO ALK INHIBITORS IN ALK-POSITIVE NON–SMALL-CELL LUNG CANCER
Amro Abdellatief,Julian R. Molina,Jose S. Pulido
Retinal Cases & Brief Reports. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
27 Precision medicine in oncology drug development: a pharma perspective
Simon J. Hollingsworth
Drug Discovery Today. 2015; 20(12): 1455
[Pubmed]  [Google Scholar] [DOI]
28 Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification
Matthew G. Hanna,Vesna Najfeld,Hanna Y. Irie,Joseph Tripodi,Anupma Nayak
SpringerPlus. 2015; 4(1)
[Pubmed]  [Google Scholar] [DOI]
29 AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers,Valerie G. Brunton,Asier Unciti-Broceta
Journal of Medicinal Chemistry. 2015;
[Pubmed]  [Google Scholar] [DOI]
30 Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?
Avisek Deyati,Rama Devi Sanam,Sreenivasa Rao Guggilla,Vijaya Rao Pidugu,Natalia Novac
Personalized Medicine. 2014; 11(4): 381
[Pubmed]  [Google Scholar] [DOI]
31 Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery
Wen-Chieh Wang,Hui-Yi Shiao,Chieh-Chien Lee,Ka-Shu Fung,Hsing-Pang Hsieh
MedChemComm. 2014; 5(9): 1266
[Pubmed]  [Google Scholar] [DOI]

 

Read this article